Monarch Network Capital has a Buy rating and a target price of Rs 330, indicating a potential upside of 14.2%. The brokerage expects the company to deliver a 17% revenue CAGR, 20% EBITDA CAGR and 41% PAT CAGR over FY26–FY28E, driven by a strong product launch pipeline. The brokerage expects EBITDA margins to remain in the 20–22% range during the period, supported by merger synergies and the scale-up of its higher-margin companion animal and human health businesses.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)